Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2021-003514-39-SE
EUCTR2021-003514-39-SE
Active, not recruiting
Phase 1

Testing E/I imbalance in autism with Bumetanide – a parallel group randomized waitlist-control trial in adolescents and adults - Testing E/I imbalance in autism with Bumetanide

Gillberg Neuropsychiatry Centre0 sites50 target enrollmentAugust 11, 2021
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
DrugsBurinex

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Gillberg Neuropsychiatry Centre
Enrollment
50
Status
Active, not recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 11, 2021
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Gillberg Neuropsychiatry Centre

Eligibility Criteria

Inclusion Criteria

  • •Autism Spectrum Disorder
  • •Age 12\-40 years old.
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range: 25
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 25
  • •F.1\.3 Elderly (\>\=65 years) no
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •Long QT syndrome
  • •Intellectual disability

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
Bumetanide in Autism Medication and Biomarker study<br>
NL-OMON44696niversitair Medisch Centrum Utrecht90
Active, not recruiting
Phase 1
Bumetanide for Autism Treatment Study
EUCTR2014-001560-35-NLBrain Center Rudolf Magnus, University Medical Center Utrecht, Department of Psychiatry, Utrecht , the Netherlands
Not yet recruiting
Not Applicable
Bumetanide for the Autism Spectrum Clinical Effectiveness TrialAutism Spectrum Disorders (ASDs)Epilepsy
NL-OMON20585niversity Medical Center Utrecht172
Active, not recruiting
Phase 1
Bumetanide treatment for autism in clinical practice trialAutism Spectrum Disorder, Attention Deficit Hyperactivity Disorder, EpilepsyMedDRA version: 20.0Level: LLTClassification code 10008520Term: Childhood autismSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 20.0Level: PTClassification code 10063844Term: Autism spectrum disorderSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 20.0Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: LLTClassification code 10061345Term: Pervasive developmental disorderSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 20.0Level: LLTClassification code 10003805Term: AutismSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 20.0Level: LLTClassification code 10034739Term: Pervasive developmental disorder NOSSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 20.0Level: LLTClassification code 10064104Term: ADHDSystem Organ Class: 10037175 - Psychiatric disordersTherapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
EUCTR2016-002875-81-NLMC Utrecht172
Completed
Phase 2
Bumetanide for the Autism Spectrum Clinical Effectiveness TrialADHDAutismAutism Spectrum Disordersepilepsy1005716710012562
NL-OMON45411niversitair Medisch Centrum Utrecht172